北京肿瘤医院两次发表江苏恒瑞PD-1单抗卡瑞利珠的临床试验论文，数问生物提供PD-L1检测，能够明显预测疗效。
原文链接：
1. Jing Huang et al, Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma. Clinical Cancer Research,2018.
2.Jing Huang et al, Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncology,2020.
